Experts weigh in after suing FDA for access to Pfizer trial data
maryannedemasi.substack.com
By Maryanne Demasi, PhD In Dec 2020, the US drug regulator (FDA) granted emergency use authorisation to Pfizer’s Covid-19 mRNA vaccine with limited data from phase III trials. Amid the urgency of the pandemic, the review of the trial data was conducted faster than usual. What would normally take an average of 10 months to review, only took the FDA 108 days.
Experts weigh in after suing FDA for access to Pfizer trial data
Experts weigh in after suing FDA for access…
Experts weigh in after suing FDA for access to Pfizer trial data
By Maryanne Demasi, PhD In Dec 2020, the US drug regulator (FDA) granted emergency use authorisation to Pfizer’s Covid-19 mRNA vaccine with limited data from phase III trials. Amid the urgency of the pandemic, the review of the trial data was conducted faster than usual. What would normally take an average of 10 months to review, only took the FDA 108 days.